IGF-2 Therapy for Diabetes Blood Glucose Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, particularly type 1 and type 2, require ongoing daily insulin injections, which are expensive, inconvenient, and can cause side effects such as low blood sugar.
Innovation Solution
The use of insulin-like growth factor 2 (IGF-2) or its variants to treat diabetes, involving daily doses administered over several days to achieve and maintain normal blood glucose levels without the need for continuous insulin therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If insulin therapy is used to treat diabetes, then blood glucose levels can be controlled, but patients require ongoing daily injections which are expensive and inconvenient
Solution Approach 1:
The patent applies preliminary action by using IGF-2 to stimulate beta cell proliferation and insulin production in advance, so that the body produces its own insulin continuously rather than requiring daily external injections. This preparatory biological action establishes endogenous insulin production capacity before the need for ongoing exogenous insulin therapy would arise.
Solution Approach 2:
The patent implements self-service by enabling the patient's own beta cells to produce insulin autonomously through IGF-2 stimulation. Once beta cell mass is restored or enhanced, the endocrine system serves itself by continuously producing endogenous insulin, eliminating dependence on external insulin injections and achieving self-regulating blood glucose control.
2Reliability
If insulin therapy is used to treat diabetes, then blood glucose levels can be controlled, but the treatment is expensive
Solution Approach 1:
The patent employs a form of disposable approach by using IGF-2 as a temporary, limited-duration treatment intervention. Instead of lifelong expensive insulin injections, a finite course of IGF-2 therapy (potentially shorter duration) stimulates lasting beta cell function, after which endogenous insulin production continues without further treatment cost, effectively replacing ongoing expensive therapy with a potentially shorter, equally or more cost-effective initial treatment.
Solution Approach 2:
The patent applies parameter changes by shifting from exogenous insulin administration to endogenous insulin production. This fundamental change in the source and mechanism of insulin delivery transforms the treatment paradigm, potentially reducing long-term costs by eliminating the need for continuous purchase and administration of expensive insulin medications.
3Reliability
If insulin therapy is used to treat diabetes, then blood glucose levels can be controlled, but side effects such as low blood sugar occur
Solution Approach 1:
The patent implements self-service through restoration of endogenous insulin production, where the patient's own beta cells autonomously regulate insulin secretion based on physiological feedback mechanisms. This self-regulating system naturally prevents hypoglycemia by adjusting insulin release according to actual blood glucose levels, eliminating the risk of overdose and low blood sugar associated with exogenous insulin therapy.
Solution Approach 2:
The patent utilizes feedback mechanisms inherent in the endocrine system, where restored or stimulated beta cells continuously monitor blood glucose levels and adjust insulin secretion accordingly. This physiological feedback loop prevents hypoglycemia by reducing or stopping insulin production when glucose levels are adequate, unlike fixed-dose exogenous insulin therapy that cannot dynamically adapt to changing glucose levels.
Data Source
AI summary
The disclosure provides for compounds, compositions, and methods of use thereof for treating diabetes (e.g., type 1 diabetes, type 2 diabetes). In some aspects, methods comprise administering first, second, third, fourth, and fifth daily doses of insulin-like growth factor 2 (“IGF-2”) or a variant thereof to the subject at respective first, second, third, fourth, and fifth different times, wherein each of the daily doses comprises at least 65 μg of IGF-2. In other aspects, compounds, compositions, and methods containing IGF-2 or variants thereof are used for treating a disorder in a patient in need thereof, such as type 1 or type 2 diabetes.